Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.

Maes A, Maes K, Vlummens P, De Raeve H, Devin J, Szablewski V, De Veirman K, Menu E, Moreaux J, Vanderkerken K, De Bruyne E.

Blood Cancer J. 2019 Nov 18;9(12):87. doi: 10.1038/s41408-019-0249-x.

2.

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.

Maes A, Maes K, De Raeve H, De Smedt E, Vlummens P, Szablewski V, Devin J, Faict S, De Veirman K, Menu E, Offner F, Spaargaren M, Moreaux J, Vanderkerken K, Van Valckenborgh E, De Bruyne E.

Br J Cancer. 2019 Jun;120(12):1137-1146. doi: 10.1038/s41416-019-0471-0. Epub 2019 May 15.

PMID:
31089208
3.

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.

Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, Heusschen R, De Raeve H, Schots R, Vanderkerken K, Caers J, Menu E.

Blood Cancer J. 2018 Nov 8;8(11):105. doi: 10.1038/s41408-018-0139-7.

4.

Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study.

Rao L, De Veirman K, Giannico D, Saltarella I, Desantis V, Frassanito MA, Solimando AG, Ribatti D, Prete M, Harstrick A, Fiedler U, De Raeve H, Racanelli V, Vanderkerken K, Vacca A.

Oncotarget. 2018 Jan 30;9(17):13366-13381. doi: 10.18632/oncotarget.24351. eCollection 2018 Mar 2.

5.

Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones.

Vander Meeren S, Heyrman B, Renmans W, Bakkus M, Maes B, De Raeve H, Schots R, Jochmans K.

Ann Hematol. 2018 Jul;97(7):1219-1227. doi: 10.1007/s00277-018-3282-0. Epub 2018 Feb 28.

PMID:
29492600
6.

Novel Tropheryma species in a lung biopsy sample from a kidney transplant recipient.

Vankeerberghen A, Jonckheere S, De Raeve H, Caluwe R, De Beenhouwer H.

Clin Microbiol Infect. 2018 May;24(5):548.e5-548.e8. doi: 10.1016/j.cmi.2017.09.011. Epub 2017 Sep 28.

7.

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.

De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E.

Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13.

8.

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.

De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K.

J Pathol. 2017 Mar;241(4):534-546. doi: 10.1002/path.4860. Epub 2017 Jan 30.

PMID:
27976373
9.

Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.

Binsfeld M, Muller J, Lamour V, De Veirman K, De Raeve H, Bellahcène A, Van Valckenborgh E, Baron F, Beguin Y, Caers J, Heusschen R.

Oncotarget. 2016 Jun 21;7(25):37931-37943. doi: 10.18632/oncotarget.9270.

10.

Chronic Malaise and a Persisting Skin Rash in an Adolescent.

Van Gysel D, De Raeve H, De Wit M.

Pediatr Dermatol. 2016 Sep;33(5):559-60. doi: 10.1111/pde.12943. No abstract available.

PMID:
27595876
11.

An Infant with a Lump on the Earlobe.

Van Gysel D, De Raeve H, Bruylants B.

Pediatr Dermatol. 2016 May;33(3):347-8. doi: 10.1111/pde.12822. No abstract available.

PMID:
27176805
12.

An unexpected complication of chronic myelomonocytic leukemia: severe renal failure due to malignant tubulo-interstitial cell infiltration.

Spapen J, Fostier K, De Raeve H, Janssens P, Spapen H.

Int J Nephrol Renovasc Dis. 2015 Dec 21;9:1-4. doi: 10.2147/IJNRD.S98528. eCollection 2016.

13.

Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.

Nur H, Rao L, Frassanito MA, De Raeve H, Ribatti D, Mfopou JK, Van Valckenborgh E, De Bruyne E, Vacca A, Vanderkerken K, Menu E.

Br J Haematol. 2014 Dec;167(5):651-63. doi: 10.1111/bjh.13092. Epub 2014 Aug 21.

PMID:
25142285
14.

Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.

Michiels JJ, Berneman Z, Gadisseur A, Lam KH, De Raeve H, Schroyens W.

Acta Haematol. 2015;133(1):56-63. doi: 10.1159/000360388. Epub 2014 Aug 7.

PMID:
25116182
15.
16.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092
17.

Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.

D'Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, De Raeve H, Muyldermans S, Caveliers V, Devoogdt N, Lahoutte T.

Theranostics. 2014 Apr 25;4(7):708-20. doi: 10.7150/thno.8156. eCollection 2014.

18.

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.

Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, McClue S, Vanderkerken K, De Bruyne E.

Oncotarget. 2014 May 30;5(10):3115-29.

19.

Echocardiographic integrated backscatter for the differentiation between aortic valve calcification and valvular myxoid degeneration in rats.

Gillis K, Bala G, Roosens B, Remory I, De Raeve H, Tierens S, Hernot S, Van Camp G, Droogmans S, Cosyns B.

Eur Heart J Cardiovasc Imaging. 2014 Sep;15(9):1042-7. doi: 10.1093/ehjci/jeu067. Epub 2014 Apr 30.

PMID:
24787702
20.

Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.

Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K.

Mol Cancer Ther. 2013 Sep;12(9):1763-73. doi: 10.1158/1535-7163.MCT-13-0123. Epub 2013 Jul 5. Erratum in: Mol Cancer Ther. 2015 Jul;14(7):1762. De Bryune, Elke [Corrected to De Bruyne, Elke].

21.

Gangliocytic paraganglioma of the duodenum: a rare entity.

De Man M, De Gendt S, De Raeve H, Vandervoort J.

Acta Gastroenterol Belg. 2012 Dec;75(4):462-3. No abstract available.

PMID:
23402095
22.

Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.

Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A, Zhivotovsky B, Jernberg-Wiklund H, Grandér D, Celsing F, Björkholm M, Vanderkerken K, Panaretakis T.

Cancer Res. 2012 Oct 15;72(20):5348-62. doi: 10.1158/0008-5472.CAN-12-0658. Epub 2012 Sep 4.

23.

In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.

Xu S, De Becker A, De Raeve H, Van Camp B, Vanderkerken K, Van Riet I.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):391-7. doi: 10.1016/j.bbrc.2012.06.118. Epub 2012 Jul 6.

PMID:
22771324
24.

Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia.

Koopmans SM, Bot FJ, Lam KH, van Marion AM, de Raeve H, Hebeda KM.

Am J Clin Pathol. 2011 Oct;136(4):618-24. doi: 10.1309/AJCP2UG9SGGWAHUA.

PMID:
21917685
25.

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.

Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.

PMID:
20530289
26.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K.

Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16.

27.

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K.

Leukemia. 2009 Oct;23(10):1894-903. doi: 10.1038/leu.2009.121. Epub 2009 Jun 4.

PMID:
19494837
28.

Multiple myeloma--an update on diagnosis and treatment.

Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B, Vanderkerken K.

Eur J Haematol. 2008 Nov;81(5):329-43. doi: 10.1111/j.1600-0609.2008.01127.x. Epub 2008 Sep 13. Review.

PMID:
18637123
29.

Recurrent myasthenia gravis due to a pleural implant 3 years after radical thymectomy.

Heyman SR, De Raeve H, Mercelis R, De Pooter C, Van Schil P.

Ann Thorac Surg. 2008 Jul;86(1):299-301. doi: 10.1016/j.athoracsur.2008.01.030.

PMID:
18573446
30.

Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma.

Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, Alvarez E, Vanderkerken K.

Br J Cancer. 2008 Jun 17;98(12):1966-74. doi: 10.1038/sj.bjc.6604388. Epub 2008 Jun 3.

31.

Paraneoplastic Opsoclonus-Myoclonus-Ataxia (OMA) syndrome in an adult patient with esthesioneuroblastoma.

Van Diest D, De Raeve H, Claes J, Parizel PM, De Ridder D, Cras P.

J Neurol. 2008 Apr;255(4):594-6. doi: 10.1007/s00415-008-0741-x. Epub 2008 Feb 4. No abstract available.

PMID:
18231703
32.

Acute myeloid leukaemia of mixed megakaryocytic and erythroid origin: a case report and review of the literature.

Daniëls L, Guerti K, Vermeulen K, De Raeve H, Van Assche E, Van de Velde AL, Berneman ZN, Van Der Planken M.

Acta Clin Belg. 2007 Sep-Oct;62(5):308-14.

PMID:
18229464
33.

Asymptomatic pheochromocytoma in the posterior mediastinum.

Bouhouch A, Hendriks JM, Lauwers PR, De Raeve HR, Van Schil PE.

Acta Chir Belg. 2007 Jul-Aug;107(4):465-7.

PMID:
17966552
34.

JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.

Michiels JJ, Commandeur S, Hoogenboom GJ, Wegman JJ, Scholten L, van Rijssel RH, De Raeve H.

Ann Hematol. 2007 Nov;86(11):793-800. Epub 2007 Aug 9. Review.

PMID:
17687555
35.

Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.

Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K, Van Camp B, Croucher P, Vanderkerken K.

Int J Cancer. 2007 Oct 15;121(8):1857-61.

36.

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.

Cancer Res. 2007 May 15;67(10):4572-7. Epub 2007 May 10.

37.

Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells.

Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, Defresne MP, Van Riet I, Van Camp B, Vanderkerken K.

Leukemia. 2007 Jul;21(7):1580-4. Epub 2007 Mar 22. No abstract available.

38.

WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.

Michiels JJ, De Raeve H, Hebeda K, Lam KH, Berneman Z, Schroyens W, Schwarz J.

Leuk Res. 2007 Aug;31(8):1031-8. Epub 2007 Mar 23. Review.

PMID:
17367853
39.

Immunomodulatory drugs as a therapy for multiple myeloma.

De Raeve H, Vanderkerken K.

Curr Pharm Biotechnol. 2006 Dec;7(6):415-21. Review.

PMID:
17168657
40.

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K.

Clin Exp Metastasis. 2006;23(5-6):291-300. Epub 2006 Nov 3.

PMID:
17086356
41.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
42.

Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.

De Bruyne E, Andersen TL, De Raeve H, Van Valckenborgh E, Caers J, Van Camp B, Delaissé JM, Van Riet I, Vanderkerken K.

Leukemia. 2006 Oct;20(10):1870-9. Epub 2006 Aug 10.

43.

Imatinib-induced eccrine squamous syringometaplasia.

Van de Voorde K, De Raeve H, Van Regenmortel N, Lambert J.

J Am Acad Dermatol. 2006 Aug;55(2 Suppl):S58-9. No abstract available.

PMID:
16843129
44.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
45.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
46.

POEMS syndrome characterized by glomeruloid angioma, osteosclerosis and multicentric Castleman disease.

Perdaens C, De Raeve H, Goossens A, Sennesael J.

J Eur Acad Dermatol Venereol. 2006 Apr;20(4):480-1. No abstract available.

PMID:
16643164
47.

The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.

Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Vande Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K.

Haematologica. 2006 May;91(5):605-12. Epub 2006 Apr 19. Erratum in: Haematologica. 2007 Nov;92(11):1584. Van de Broek, Isabelle [corrected to Vande Broek, Isabelle].

48.

Post-traumatic severe fat embolism syndrome with uncommon CT findings.

Van den Brande FG, Hellemans S, De Schepper A, De Paep R, Op De Beeck B, De Raeve HR, Jorens PG.

Anaesth Intensive Care. 2006 Feb;34(1):102-6. Review.

49.

Bortezomib-induced Sweet's syndrome.

Van Regenmortel N, Van de Voorde K, De Raeve H, Rombouts S, Van de Velde A, Lambert J, Schroyens W.

Haematologica. 2005 Dec;90(12 Suppl):ECR43.

50.

The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model.

Caers J, Günthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I, Van Camp B, Vanderkerken K.

Br J Haematol. 2006 Feb;132(4):469-77.

PMID:
16412019

Supplemental Content

Loading ...
Support Center